Navigation Links
Pathogenica Achieves CE Marking for HAI BioDetection Kit
Date:8/14/2013

BOSTON, Aug. 14, 2013 /PRNewswire/ -- Pathogenica, Inc. (www.pathogenica.com) announced today that the company has achieved the CE mark under the European Directive on In Vitro Diagnostic Medical Devices for its HAI BioDetection kit that runs on the Ion PGM™ benchtop sequencer.  This milestone marks the HAI BioDetection CE-IVD kit as the first sequence-based infectious disease diagnostic kit on the market.

"The kit and interpretation software system provides clinicians with a revolutionary diagnostic tool for the identification of disease-causing bacteria and accompanying antibiotic resistance markers in a clinically actionable timeframe," said Yemi Adesokan, Pathogenica's CEO.  "Our team is proud to be supporting the evolving way healthcare providers will routinely manage patient care and treatment options."

Healthcare associated infections (HAIs) are recognized as a severe health threat associated with increases in cost, morbidity, and mortality.  Although screening has enabled reductions in some facilities' MRSA infection rates, recent lethal outbreaks of antibiotic resistant Acinetobacter, Enterococcus, Klebsiella, and Pseudomonas emphasize the diversity of organisms that threaten patient health.  Intensive care units (ICUs) and other hospital wards with patients particularly susceptible to infection may benefit from advanced screening measures.

The HAI BioDetection CE-IVD kit enables identification of the causative agents of 95% of nosocomial infections in a single assay, enabling clinicians to rapidly take appropriate precautions for specific patients.  The assay not only identifies the pathogen but also includes a broad panel of 10 resistance genes (including mecA, vanA, KPC and TEM), enhancing a clinician's ability to choose the appropriate antimicrobial therapy and practice proper antibiotic stewardship.  Studies have shown active surveillance to be a valuable component of a quality infection control program that enhances treatment decisions, improves patient care, and reduces costs due to extended length of stay, unnecessary isolation, and nursing time.

The HAI BioDetection CE-IVD kit prepares samples for sequencing from DNA extracted from isolates, colonies, positive blood culture, urine, rectal swabs, and stool.  This broad array of sample types makes Pathogenica's assay a strong fit for identifying pathogens associated with enteric diseases, bloodstream infections and respiratory disorders – the key profile for HAIs in the US and EU.  Furthermore, the assay requires no pre-culturing for urine, rectal swabs, and stool, enabling a streamlined lab workflow and clinically actionable turnaround (12 hours from DNA extraction to results) for patients affected by urinary tract infections or enteric disorders.

"Culture independent sequencing is a great step forward for clinical applications," said Pathogenica co-founder George Church, Prof. of Genetics at Harvard Medical School.  "Pathogenica has delivered a next-generation sequencing diagnostic tool that provides identification and antibiotic resistance information for improved infection control and therapeutic decision making."

"Thought leaders in infection control departments have been enthusiastic about our rapid high resolution test," said Adesokan. "Pathogenica produces clinically superior and actionable results more rapidly after sample collection than other technologies such as MALDI-TOF and PFGE, which require pre-cultured samples."

In validation testing, the HAI BioDetection CE-IVD kit demonstrated a 100% correct identification rate for 771 bacterial samples.  From specific clinical specimens, the kit identified 100% of Enterococcus positive rectal swabs, with an 89% detection rate of vanA, and achieved 92% concordance with microbial culture from stool for a broad set of bacterial targets.

About the CE-marked HAI BioDetection Assay and Software

The Pathogenica HAI BioDetection CE-IVD kit is a qualitative in vitro test for the rapid identification of bacterial organisms and resistance genes (see Pathogenica website for full list). The organisms and resistance genes can be identified from pure bacterial cultures, colonies selected from an agar plate, positive blood culture bottles, or directly from urine, rectal swabs, or stool.

Contact:

Yemi Adesokan
+1 949 351 9954

Read more news from Pathogenica.


'/>"/>
SOURCE Pathogenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
2. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
3. Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
4. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
5. Ekahau Achieves 45% Year-over-Year Revenue Growth and Strong Adoption of Safety Alert Solution in 2012
6. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
7. Idem Translations Achieves EN 15038:2006 Certification
8. Idem Translations Achieves ISO 13485:2003 Certification
9. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
10. TriCore Solutions Achieves SAP Gold Partner Status
11. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring and Diagnostic ... connectivity to reduce the amount of wiring in a healthcare facility and allow ... devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and other wearable ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating ... prostate circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on ... Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los ...
(Date:5/23/2017)... ... 2017 , ... Cambridge Semantics , the leading provider of Big Data ... Conference and Expo in Boston May 23-25 with a featured speaker and solution ... Data Lake is also a finalist for the Best of Show award. , James ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):